CN1424043A - Kakonein eye drops - Google Patents
Kakonein eye drops Download PDFInfo
- Publication number
- CN1424043A CN1424043A CN 02159344 CN02159344A CN1424043A CN 1424043 A CN1424043 A CN 1424043A CN 02159344 CN02159344 CN 02159344 CN 02159344 A CN02159344 A CN 02159344A CN 1424043 A CN1424043 A CN 1424043A
- Authority
- CN
- China
- Prior art keywords
- puerarin
- sodium
- eye drop
- mixture
- drop according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
An eyedrops of kakonein for preventing and treating glaucoma contains kakonein, cosolvent, antioxidizing agent, metal complex, osmotic pressure regulator, antiseptic, pH regulator, and distilled water. Its advantages are high curative effect, low by-effect, and protecting vision.
Description
Technical field
The invention belongs to medicine field, specifically a kind of puerarin eye drop.
Background technology
Glaucoma is one of common senile disease, and the people more than 40 years old has 2% to suffer from this disease approximately, and along with the aging of population, sickness rate improves year by year.Though but the glaucoma operative treatment, medical treatment is still one of important means.Some treats glaucomatous medicine at present on the market, and the effect of reduction intraocular pressure (IOP) is only arranged usually.Therefore, after patient's administration, though make sxs such as headache because of reducing IOP, vision still continues to descend.Reason is that these medicines when reducing IOP, also can make visual organ blood flow minimizings such as retina, and nutrition supply is bad, and then visual performance is gone down.Picture timolol eye drop the side effect of decreased heart rate also can occur in treatment.So a good anti-glaucoma medicine should reduce IOP, go back otherwise the supply of blood flow of minimizing (preferably increasing) visual organ, and side effect is little.
Summary of the invention
The technical problem to be solved in the present invention is at above-mentioned deficiency, develops the puerarin eye drop that a kind of glaucoma is used.
The percentage by weight that comprises composition of the present invention is: puerarin 0.2%-2%, cosolvent 2%-8%, antioxidant 0.03%-0.2%, metal chelating agent 0.03%-0.2%, osmotic pressure regulator 3%-9%, antiseptic 0.002%-0.3%, an amount of PH regulator, all the other are distilled water.
Advantage of the present invention is that glaucoma is effective, and safe and convenient to use, side effect is little, and vision is had protective effect.The generation of these advantages is because it has beta-receptor blocking effect widely, can effectively reduce intraocular pressure, can improve the microcirculation of ophthalmic simultaneously again, increases the supply of blood flow of main visual organ; The present invention drip with after, the side effect that also can not produce decreased heart rate.
The specific embodiment
The invention will be further described in conjunction with the embodiments for face.
Embodiment 1: in 1000 milliliters of puerarin eye drops, the percentage by weight of each composition that is contained is: puerarin 0.5%, polyvinylpyrrolidone 8%, disodiumedetate 0.1%, sodium pyrosulfite 0.1%, benzalkonium bromide 0.01%, sodium chloride 6%, sodium hydroxide are an amount of, all the other are distilled water.
Sodium hydroxide is meant in right amount: by being added dropwise to the 1M sodium hydroxide solution, make join solution pH value be fit to eye liquid.The 1M sodium hydroxide solution prepares in advance, and the 1M sodium hydroxide solution is illustrated in 1 mole sodium hydroxide in every liter of solution.
Manner of formulation at present embodiment is: after 1) puerarin, polyvinylpyrrolidone, disodiumedetate, sodium pyrosulfite being prepared with corresponding percentage, adding sodium chloride is an amount of, uses dissolved in distilled water, by stirring it is dissolved fully; 2) regulate pH value with the 1M sodium hydroxide solution and be fit to eye liquid; 4) add distilled water to 1000 milliliter, stir, and be filtered to clarification, clear filtrate is sub-packed in the plastics eyedrops bottle and gets final product.
Embodiment 2: in 1000 milliliters of puerarin eye drops, the percentage by weight of each composition that contains is: puerarin 1%, para-amino benzoic acid 5%, disodiumedetate 0.05%, sodium thiosulfate 0.2%, thimerosal 0.01%, the sodium bicarbonate of borate 5%, 2% is an amount of, all the other are distilled water.
Embodiment 3: in 1000 milliliters of puerarin eye drops, the percentage by weight of each composition that contains is: puerarin 1.5%, polyvinyl alcohol 6%, disodiumedetate 0.1%, sodium citrate 0.2%, phenethanol 0.1%, sodium chloride 5% borate buffer solution is an amount of, all the other are distilled water.
Embodiment 4: in 1000 milliliters of puerarin eye drops, the percentage by weight of each composition that contains is: puerarin 2%, polysorbate 3%, disodiumedetate 0.2%, sodium sulfite 0.2%, nipalgin 0.01%, Borax 4%, phosphate buffer are an amount of, all the other are distilled water.
Clinical trial one: to 161 examples totally 273 primary open angle glaucoma patient adopt parallel control and open design at random, the glaucoma of Application Example 1 preparation carries out clinical trial with the puerarin eye drop, the total effective rate of therapeutic outcome is 86.8%.
Clinical trial two: to 120 examples totally 120 primary open angle glaucoma patients adopt parallel control at random, the glaucoma of Application Example 1 preparation carries out clinical trial with the puerarin eye drop, the total effective rate of therapeutic outcome is 88.3%.And in the treatment of this clinical trial, do not occur because of playing the side effect that heart rate slows down with this guiding drug yet.
Clinical trial three: to other various glaucoma patient with other the dissatisfied person of intraocular pressure effect of drugs falls, add glaucoma with the present invention's preparation with the puerarin eye drop after, certain effect of falling intraocular pressure is also arranged, total effective rate is 70.6%.
Clinical trial four: to the acute high intraocular pressure model of rabbit, with the puerarin eye drop, this eye drop can be absorbed by its ocular tissue, no matter is a drug with the glaucoma of the present invention preparation, and still repeatedly medication all has reducing iop, and not seeing has untoward reaction.
Glaucoma of the present invention puerarin eye drop, when being used for the treatment of the primary open angle glaucoma patient, its usage is, every day 2 times, each 1, continuous 3 weeks, its effective percentage just can reach more than 80%, and the phenomenon of decreased heart rate does not take place patient yet.
The used puerarin of the present invention is the pure product of effective components of Chinese medicinal, belongs to osajin.
Claims (8)
1, a kind of puerarin eye drop, it is characterized in that the percentage by weight that it comprises composition is: puerarin 0.2%-2%, cosolvent 2%-8%, antioxidant 0.03%-0.2%, metal chelating agent 0.03%-0.2%, osmotic pressure regulator 3%-9%, antiseptic 0.002%-0.3%, an amount of PH regulator, all the other are distilled water.
2, puerarin eye drop according to claim 1 is characterized in that puerarin is the pure product of effective components of Chinese medicinal, belongs to osajin.
3, puerarin eye drop according to claim 1, it is characterized in that cosolvent is selected from least a in cyclodextrin, polypropylene based polymers, polyvinyl alcohol, polyvidon, para-amino benzoic acid, the polysorbate, or at least a in their mixture.
4, puerarin eye drop according to claim 1, it is characterized in that anticatalyst is selected from least a in sodium sulfite, sodium sulfite, sodium pyrosulfite, sodium metasulfite, sodium thiosulfate, sodium citrate, the ascorbic acid, or at least a in their mixture.
5, puerarin eye drop according to claim 1, it is characterized in that metal chelating agent is selected from least a in ethylenediaminetetraacetic acid one sodium salt, disodium EDTA, EDTA Dipotassium salt, ethylenediaminetetraacetic acid four potassium salt, or at least a in their mixture.
6, puerarin eye drop according to claim 1 is characterized in that osmotic pressure regulator is selected from least a in sodium chloride, borate, the Borax, or at least a in their mixture.
7, puerarin eye drop according to claim 1 is characterized in that the PH regulator is selected from least a in phosphate buffer, borate buffer solution, sodium hydroxide, the sodium bicarbonate, or at least a in their mixture.
8, puerarin eye drop according to claim 1 is characterized in that antiseptic is selected from least a in thimerosal, parabens, phenethanol, the benzalkonium bromide, or at least a in their mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159344 CN1424043A (en) | 2002-12-23 | 2002-12-23 | Kakonein eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159344 CN1424043A (en) | 2002-12-23 | 2002-12-23 | Kakonein eye drops |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1424043A true CN1424043A (en) | 2003-06-18 |
Family
ID=4753292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02159344 Pending CN1424043A (en) | 2002-12-23 | 2002-12-23 | Kakonein eye drops |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1424043A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316975C (en) * | 2005-09-16 | 2007-05-23 | 四川三精升和制药有限公司 | Puerarin prepn for eye and its prepn process |
| CN101167710B (en) * | 2007-10-26 | 2010-04-21 | 张咏梅 | Chloromycetin eyedrops with long quality guaranteed period and preparation method thereof |
| CN102204931A (en) * | 2011-05-26 | 2011-10-05 | 浙江工业大学 | Amiotide eye drop containing composite bacteriostatic agent |
| CN104688672A (en) * | 2014-12-29 | 2015-06-10 | 浙江莎普爱思药业股份有限公司 | Application of puerarin gel eye drop in preparation of drugs for treating ischemic ocular fundus diseases |
| CN108066315A (en) * | 2016-11-11 | 2018-05-25 | 天津中医药大学 | Puerarin and scutellarin lipid nano particle eye-drops preparations and preparation method thereof |
| CN110755376A (en) * | 2019-12-05 | 2020-02-07 | 河南省人民医院 | Vorinostat water-soluble eye drops and preparation method thereof |
-
2002
- 2002-12-23 CN CN 02159344 patent/CN1424043A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316975C (en) * | 2005-09-16 | 2007-05-23 | 四川三精升和制药有限公司 | Puerarin prepn for eye and its prepn process |
| CN101167710B (en) * | 2007-10-26 | 2010-04-21 | 张咏梅 | Chloromycetin eyedrops with long quality guaranteed period and preparation method thereof |
| CN102204931A (en) * | 2011-05-26 | 2011-10-05 | 浙江工业大学 | Amiotide eye drop containing composite bacteriostatic agent |
| CN104688672A (en) * | 2014-12-29 | 2015-06-10 | 浙江莎普爱思药业股份有限公司 | Application of puerarin gel eye drop in preparation of drugs for treating ischemic ocular fundus diseases |
| CN108066315A (en) * | 2016-11-11 | 2018-05-25 | 天津中医药大学 | Puerarin and scutellarin lipid nano particle eye-drops preparations and preparation method thereof |
| CN110755376A (en) * | 2019-12-05 | 2020-02-07 | 河南省人民医院 | Vorinostat water-soluble eye drops and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fluorouracil Filtering Surgery Study Group | Three-year follow-up of the Fluorouracil Filtering Surgery Study | |
| AU695937B2 (en) | Intraocular irrigating solution containing agent for controlling IOP | |
| US20110301164A1 (en) | Method of administering ophthalmic fluids | |
| US20050059639A1 (en) | Ophthalmic compositions and method for treating eye discomfort and pain | |
| Quigley et al. | Pilocarpine Ocuserts: long-term clinical trials and selected pharmacodynamics | |
| NZ503063A (en) | Sustained release ophthalmic compositions containing water soluble medicaments | |
| US20210259961A1 (en) | Pharmaceutical composition for preventing and treating nitm and medical use thereof | |
| CN101278908B (en) | Eye drop capable of significantly increasing medicament effect | |
| CN1424043A (en) | Kakonein eye drops | |
| US20190298651A1 (en) | Methods of Eye Treatment Using Therapeutic Compositions Containing Dipyridamole | |
| JPH0672869A (en) | Aqueous medicine composition of sodium chromoglycate | |
| EP2734188A1 (en) | Compositions and methods for the treatment of ocular surface allergies | |
| CN102008488B (en) | Triamcinolone acetonide ophthalmic preparation and preparation method thereof | |
| CN1132584C (en) | Myopia treating eye drop | |
| EP1121929B1 (en) | Composition comprising di- and trisodiumsalts of echinochrome for treating ocular conditions | |
| CN115212200B (en) | Puerarin-containing compound preparation for treating diabetic complications and preparation method thereof | |
| US20100323978A1 (en) | Non-aqueous oil delivery system for ophthalmic drugs | |
| CN110200904B (en) | Intraocular pressure reducing sustained-release eye drop composition and preparation method thereof | |
| Milton | Pr IOPIDINE® | |
| CN1128656A (en) | Application of anisodamine for prepn. of eye drops for curing pyopia | |
| EP2303256A1 (en) | Compounds useful for the prevention or treatment of accomodative asthenopia | |
| CN1965854A (en) | Moisturizing eye drop and preparation process therof | |
| Jones et al. | Control of glaucoma by reduced dosage guanethidine-adrenaline formulation. | |
| CN114306228A (en) | Diquafosol sodium eye drops and preparation method thereof | |
| CN102973594A (en) | Ophthalmic preparation containing oxygen micro-capsules and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |